Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625633 · ClinicalTrials.gov registry record · Phase 2
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
A Phase 2 study of Warts, sponsored by Western Institute for Veterans Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT05625633: Recruiting Phase 2 study of Warts, sponsored by Western Institute for Veterans Research.
NCT05625633 is a Phase 2 study of Warts that is actively recruiting participants, run by Western Institute for Veterans Research. The registered enrollment target is 120 participants, below the 205-participant average among 7 other Warts trials with a reported enrollment target (41% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05625633, a Phase 2 study of Warts, is actively recruiting participants, sponsored by Western Institute for Veterans Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Primary Outcome
Assessing the efficacy/therapeutic response of HPV vaccination for the treatment of refractory cutaneous warts, classified as: (1) complete response (CR; complete clearance of warts); (2) partial response (PR; any decrease in lesion number or size); or (3) no response (NR; no change or increase in lesion number or size)
Conditions Studied
Interventions
- OTHER Normal Saline
- BIOLOGICAL Human Papillomavirus 9-valent Vaccine, Recombinant
Study Locations (2)
Utah
- University of Utah Midvalley Health Center - Salt Lake City
- VA Salt Lake City Health Care System - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT05625633 shows while recruiting
NCT05625633 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 205-participant average among 7 other Warts trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Warts appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT05625633 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05625633 about?
NCT05625633 is a clinical study titled "Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts". This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
What is the current status of trial NCT05625633?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-03-25. Estimated completion is 2026-12.
What conditions does trial NCT05625633 study?
This clinical trial studies the following conditions: Warts.
What interventions are being tested in trial NCT05625633?
The interventions under investigation include: Normal Saline (OTHER), Human Papillomavirus 9-valent Vaccine, Recombinant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05625633?
This trial is sponsored by Western Institute for Veterans Research, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05625633 being conducted?
This trial has 2 study locations across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Warts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Candin Safety & Efficacy Study for the Treatment of Warts
COMPLETED · Phase 2
-
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
RECRUITING · Phase 1
-
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
RECRUITING
-
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
RECRUITING · Phase 3
-
Microwave Treatment of Common and Plantar Warts
ACTIVE NOT RECRUITING · NA
-
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI